Brokerages Set The Beauty Health Company (NASDAQ:SKIN) PT at $6.50

Shares of The Beauty Health Company (NASDAQ:SKIN) have been given a consensus recommendation of “Reduce” by the twelve analysts that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $6.50.

Several equities research analysts recently commented on SKIN shares. DA Davidson reiterated a “buy” rating and set a $5.00 price target on shares of Beauty Health in a research note on Friday, March 15th. TD Cowen lifted their price target on shares of Beauty Health from $2.50 to $4.00 and gave the stock a “market perform” rating in a research note on Wednesday, March 13th. Piper Sandler reiterated an “underweight” rating and set a $3.00 price target (up from $2.00) on shares of Beauty Health in a research note on Wednesday, March 13th. Canaccord Genuity Group lifted their price target on shares of Beauty Health from $3.00 to $4.00 and gave the stock a “hold” rating in a research note on Thursday, March 14th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $4.00 price target (up from $3.00) on shares of Beauty Health in a research note on Wednesday, March 13th.

Beauty Health Stock Performance

NASDAQ:SKIN opened at $3.22 on Friday. The company has a debt-to-equity ratio of 12.43, a quick ratio of 5.28 and a current ratio of 6.07. The stock has a market capitalization of $397.44 million, a P/E ratio of -4.18 and a beta of 1.01. The company has a 50 day moving average price of $3.66 and a 200 day moving average price of $3.43. Beauty Health has a fifty-two week low of $1.35 and a fifty-two week high of $13.06.

Beauty Health (NASDAQ:SKIN) last released its earnings results on Tuesday, March 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. Beauty Health had a negative net margin of 25.65% and a negative return on equity of 18.85%. The company had revenue of $96.80 million for the quarter, compared to analyst estimates of $87.22 million. During the same period in the prior year, the business earned $0.03 EPS. The firm’s quarterly revenue was down 1.3% on a year-over-year basis. Equities research analysts forecast that Beauty Health will post -0.1 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of SKIN. Dark Forest Capital Management LP boosted its holdings in shares of Beauty Health by 583.0% in the third quarter. Dark Forest Capital Management LP now owns 377,114 shares of the company’s stock valued at $2,270,000 after acquiring an additional 321,898 shares in the last quarter. Olympiad Research LP purchased a new stake in shares of Beauty Health in the third quarter valued at about $287,000. Braidwell LP purchased a new stake in shares of Beauty Health in the third quarter valued at about $9,790,000. Graham Capital Management L.P. purchased a new stake in shares of Beauty Health in the third quarter valued at about $1,057,000. Finally, Aigen Investment Management LP purchased a new stake in shares of Beauty Health in the third quarter valued at about $102,000. 93.26% of the stock is owned by hedge funds and other institutional investors.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.